Clinical trial · Interventional
Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer
Accuracy of Magnetic Resonance Imaging (MRI) in Predicting Aggressiveness of Early Breast Cancer According to Molecular Subtypes Identified by ER PR and HER-2 Status
NCT01597999CI-TRIAL-00009057unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study examines the additional benefits of magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Invasive Breast Cancer | Invasive Breast Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- No treatment
- description
- Accuracy of magnetic resonance imaging (MRI) in predicting aggressiveness of early breast cancer according to molecular subtypes identified by ER PR and HER-2 status ( Additional benefits of magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features )
- interventionNames
- Radiation: MRI
Primary outcomes (1)
- measure
- study the benefits of DCE-MRI using Gadovist in prognostic determination of early invasive breast cancer
- timeFrame
- 1 year
- description
- The benefits of breast tumor diagnosis from DCE-MRI in early invasive breast cancer with poor prognostic features
Secondary outcomes (1)
- measure
- ascertain the accuracy of pre-operative DCE-MRI in terms of detection and characterization of breast cancer, as compared to tissue biopsy.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with invasive ductal carcinoma * Patients undergoing DCE-MRI scan which are assessed according to BI-RADS lexicon * Breast cancer patients with pathological diagnosed invasive ductal carcinoma with hormonal receptor (ER, PR and HER-2) response * Patients who have signed on informed consent form Patients will undergo MRI imaging and the physicians will practice according to practice guidelines. Exclusion Criteria: * Patients under 18 years old or during pregnancy * Patients with MRI's contraindications e.g. patients with cardiac pacemaker or are allergic to MRI contrast agent Patients with unstable clinical abnormality and might get unexpected clinical treatment
References
Publications (0)
Data not yet available
No reference posted for this study.